申请人:Merck Sharp & Dohme B.V.
公开号:US20150329545A1
公开(公告)日:2015-11-19
The invention relates to FSH receptor antagonist according to general formula I
or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders.
该发明涉及一般式I的FSH受体拮抗剂或其药学上可接受的盐,以及含有该化合物的药物组合物。这些化合物可用于治疗和预防子宫内膜异位症,治疗和预防绝经前和围绝经期激素依赖性乳腺癌,避孕以及治疗子宫肌瘤和其他与月经有关的疾病。